Frequently Asked Questions

What is meningococcal disease?

Often referred to as meningococcal meningitis or meningococcemia, it is a serious and potentially fatal bacterial infection that most often causes severe swelling of the membranes surrounding the brain and spinal cord (meningitis) or a serious blood infection (meningococcemia).1

How does meningococcal disease spread?

The disease is spread person-to-person through the exchange of respiratory and throat secretions or saliva.2 Teens and preteens are at greater risk as they tend to share everything from water bottles and pizza slices to eating utensils and kisses.3,4

How serious is meningococcal disease?

Though rare, it may be extremely serious. About 1 in 10 people with meningococcal disease die even with appropriate antibiotic treatment.2 Of those who recover, up to 1 in 5 suffer from some serious consequence, like permanent hearing loss, loss of an arm or leg, or brain damage.5

What are the symptoms of meningococcal disease?

Unfortunately, first symptoms often seem like a cold or the flu, so it’s easy to misdiagnose.6 But even with appropriate treatment, it can cause death in as little as 24-48 hours from onset of symptoms.4

Who is at greater risk for meningococcal disease?

Although anyone can get meningococcal disease, adolescents are at an increased risk.7

Is there a way to help protect my child against meningococcal disease?

Vaccination is the best way to help protect your child. The majority of cases of meningococcal disease in adolescents in the United States may be preventable.2

When should my child be vaccinated against meningococcal disease?

The Centers for Disease Control and Prevention (CDC) recommends vaccination with a meningococcal vaccine for all adolescents 11 through 18 years of age.8 Talk to your healthcare provider about having your child vaccinated as soon as possible.

If a friend of my child is diagnosed with meningococcal disease, what should I do to help protect my child?

Seek medical care immediately

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with another US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

References

  1. Meningitis: Overview. National Foundation for Infectious Diseases Web site. http://www.nfid.org/meningitis/. Accessed March 3, 2010.
  2. Meningococcal: Questions and answers. Immunization Action Coalition Web site. http://www.immunize.org/catg.d/p4210.pdf. Accessed March 3, 2010.
  3. Meningitis: Prevention. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/about/prevention.html. Accessed February 18, 2010.
  4. Meningococcal meningitis. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed March 3, 2010.
  5. Meningococcal meningitis. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/2003/fs141/en/. Accessed February 18, 2010.
  6. Meningitis: Myths about meningococcal disease. National Foundation for Infectious Diseases Web site. http://www.nfid.org/meningitis/consumers_myths.html. Accessed March 3, 2010.
  7. Meningitis: People most at risk. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/high-risk/index.html. Accessed February 18, 2010.
  8. Meningitis: Meningococcal vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/vaccine-info.html. Accessed March 3, 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel